<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587975</url>
  </required_header>
  <id_info>
    <org_study_id>DUMC-EVOG-BONE</org_study_id>
    <nct_id>NCT02587975</nct_id>
  </id_info>
  <brief_title>Effect of Evogliptin on Bone Metabolism in Human</brief_title>
  <official_title>Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DongGuk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DongGuk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to measure the effect of evogliptin on bone metabolism in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentration of C-terminal telopeptide after treatment in comparison with the baseline</measure>
    <time_frame>Predose and 1, 2, 3, 4, 6, 14, 20, 24 h postdose on Day 1 and Day 2</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Evogliptin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral administration of 2 tablets of evogliptin 5 mg with water 250 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin</intervention_name>
    <description>10 mg</description>
    <arm_group_label>Evogliptin 10 mg</arm_group_label>
    <other_name>DA-1229</other_name>
    <other_name>Suganon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal healthy women (at least 5 years)

          -  BMI 18~30 kg/m2

        Exclusion Criteria:

          -  Presence or history of hypersensitivity or allergic reactions to any drug

          -  Clinically relevant abnormal medical history or present disease

          -  Presence or history of drug abuse

          -  Participation in other clinical trial within 2 months before dose.

          -  Bood donation during 2 months or apheresis during 1 month before the study.

          -  Use of a prescription medicine, herbal medicine within 2 weeks or over-the-counter
             medication or vitamin substances within 1 week before dose.

          -  Use of any drug which can affect bone metabolism such as sex hormones or their
             receptor related medicine, calcitonin or parathyroid hormone related medicine,
             systemic corticosteroid, bisphosphate, or etc.

          -  Smoking of more than 10 cigarettes/days within 3 months before first dose.

          -  Use of alcohol over 21 units/weeks

          -  Subject judged not eligible for study participation by investigator.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Namyi Gu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongguk University College of Medicine and Ilsan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Namyi Gu, MD, PhD</last_name>
    <phone>+82-31-961-8440</phone>
    <email>namyi.gu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Namyi Gu, MD, PhD</last_name>
      <phone>+82-31-961-8440</phone>
      <email>namyi.gu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>July 21, 2016</last_update_submitted>
  <last_update_submitted_qc>July 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>DongGuk University</investigator_affiliation>
    <investigator_full_name>Namyi Gu</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

